Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate CNS prophylaxis study in diffuse large B-cell lymphoma
2015-000591-97Phase 3Completed
- Sponsor
- Kooperativní lymfomová skupina
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Kooperativní lymfomová skupina. Primary endpoint: Cumulative incidence of CNS relapse. Started May 2015; status: completed.
02
Drugs
methotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2015-000591-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000591-97.